NCT06288191View on ClinicalTrials.gov

Neoadjuvant Nivolumab and Relatlimab in Cutaneous Squamous Cell Carcinoma

PHASE2RecruitingINTERVENTIONAL

Enrollment

20

Participants

Timeline

Start Date

June 21, 2024

Primary Completion Date

September 30, 2026

Study Completion Date

July 31, 2036

Conditions

Cutaneous Squamous Cell Carcinoma

Interventions

DRUG

Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combination

Dual inhibition of the distinct LAG3 and PD-1 checkpoint pathways

Trial Locations (1)

2065

RECRUITING

Melanoma Institute Australia, Wollstonecraft

Sponsors

Collaborators (1)

Bristol-Myers Squibb

All Listed Sponsors

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Melanoma Institute Australia

OTHER